VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer
Hlavní autoři: | , , , , , , , , , , , , , , |
---|---|
Médium: | Conference item |
Vydáno: |
American Society of Clinical Oncology
2018
|